High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539

C. Leland Rogers, Minhee Won, Michael A. Vogelbaum, Arie Perry, Lynn S. Ashby, Jignesh M. Modi, Anthony M. Alleman, James Galvin, Shannon E. Fogh, Emad Youssef, Nimisha Deb, Young Kwok, Clifford G. Robinson, Hui Kuo Shu, Barbara J. Fisher, Valerie Panet-Raymond, William G. McMillan, John F. de Groot, Peixin Zhang, Minesh P. Mehta

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Background: Phase 2 cooperative group meningioma trial assessing the safety and efficacy of risk-adaptive management strategies. This is the initial analysis of the high-risk cohort. Methods and Materials: High-risk patients were those with a new or recurrent World Health Organization (WHO) grade III meningioma of any resection extent, recurrent WHO grade II of any resection extent, or new WHO grade II after subtotal resection. Patients received intensity-modulated radiotherapy (IMRT) using a simultaneous integrated boost technique (60 Gy high dose and 54 Gy low dose in 30 fractions). Three-year progression-free survival (PFS) was the primary endpoint. Adverse events (AEs) were scored per NCI Common Terminology Criteria for Adverse Events version 3. Results: Of 57 enrolled patients, 53 received protocol treatment. Median follow-up was 4.0 years (4.8 years for living patients). Two patients withdrew without progression before year 3; for the remaining 51 patients, 3-year PFS was 58.8%. Among all 53 protocol-treated patients, 3-year PFS was 59.2%. Three-year local control was 68.9%, and overall survival was 78.6%. Of 51 patients, 1 patient (1.9%) experienced a late grade-5 necrosis-related AE. All other acute (23 of 53 patients) and late (21 of 51 patients) AEs were grades 1 to 3. Conclusions: Patients with high-risk meningioma treated with IMRT (60 Gy/30) experienced 3-year PFS of 58.8%. Combined acute and late AEs were limited to grades 1 to 3, except for a single necrosis-related grade 5 event. These results support postoperative IMRT for high-risk meningioma and invite ongoing investigations to improve outcomes further.

Original languageEnglish
Pages (from-to)790-799
Number of pages10
JournalInternational Journal of Radiation Oncology Biology Physics
Volume106
Issue number4
DOIs
StatePublished - Mar 15 2020

Fingerprint Dive into the research topics of 'High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539'. Together they form a unique fingerprint.

  • Cite this

    Rogers, C. L., Won, M., Vogelbaum, M. A., Perry, A., Ashby, L. S., Modi, J. M., Alleman, A. M., Galvin, J., Fogh, S. E., Youssef, E., Deb, N., Kwok, Y., Robinson, C. G., Shu, H. K., Fisher, B. J., Panet-Raymond, V., McMillan, W. G., de Groot, J. F., Zhang, P., & Mehta, M. P. (2020). High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539. International Journal of Radiation Oncology Biology Physics, 106(4), 790-799. https://doi.org/10.1016/j.ijrobp.2019.11.028